Skip to main content

#151454

Bmx Cre ERT2 Mouse

Cat. #151454

Bmx Cre ERT2 Mouse

Cat. #: 151454

Sub-type: Mouse

Availability: 8-10 weeks

Disease: Cancer

Model: Conditional KO

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ralf H. Adams

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Handling
Target Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: Bmx Cre ERT2 Mouse
  • Research fields: Developmental biology;Genetics;Immunology;Neurobiology;Tissue-specific biology
  • Tool sub type: Mouse
  • Disease: Cancer
  • Model: Conditional KO
  • Conditional: Yes
  • Conditional description: Conditional Cre-ERT2 expression under Bmx promoter enabling tissue-specific recombinase in arterial endothelial cells; inducible Cre activity by treatment with hormone (tamoxifen) enabling inducible translocation of Cre-ERT2 to nucleus.
  • Description: The estragen receptor (ERT2) under the Bone marrow x (Bmx) promoter (Bmx-Cre-ERT2) mouse exhibits tissue-specific expression of an inducible Cre-ERT2 fusion protein, enabling tamoxifen-induced Cre recombinase activity in arterial endothelial cells. The Bmx-Cre-ERT2 mouse is an ideal tool in the study of gene function in angiogenesis, atherosclerosis and neovascularisation. Administration of tamoxifen induces nuclear translocation of the Cre-ERT2 fusion protein, and subsequent Cre recombinase activity, allowing knockout/knockin/transgene studies of loxP flanked genes in endothelial cells.Non-induced Bmx-Cre-ERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Bmx-Cre-ERT2 mice demonstrate high penetrance in endothelial cells (95%+), significantly higher than existing endothelial Cre models currently available.
  • Genetic background: A Bmx-Cre-ERT2 transgene vector, containing a genomic VECad promoter fragment fused to a Cre-ERT2 cDNA, was injected into fertilised embryos (C57BL/6 or FVB/N). Founder lines were back-crossed to establish mice heterozygous for the Bmx-Cre-ERT2 transgene.
  • Zygosity: Heterozygous
  • Production details: A Bmx-Cre-ERT2 transgene vector, containing a genomic VECad promoter fragment fused to a Cre-ERT2 cDNA, was injected into fertilised embryos (C57BL/6 or FVB/N). Founder lines were back-crossed to establish mice heterozygous for the Bmx-Cre-ERT2 transgene.

Handling

  • Shipping conditions: Embryo/Spermatoza- Dry Ice

Target Details

  • Target: BMX, CreERT2

References

  • Murphy et al. 2014. Proc Natl Acad Sci U S A. 111(50):18007-12. PMID: 25468970.
  • Constitutively active Notch4 receptor elicits brain arteriovenous malformations through enlargement of capillary-like vessels.
  • Noels et al. 2014. Arterioscler Thromb Vasc Biol. 34(6):1209-20. PMID: 24723559.
  • Schober et al. 2014. Nat Med. 20(4):368-76. PMID: 24584117.
  • Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice.
  • MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1.
  • Ehling et al. 2013. Development. 140(14):3051-61. PMID: 23785053.
  • Notch controls retinal blood vessel maturation and quiescence.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.